Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling

Hypertension Research

Volumn 34, Issue 9, 2011, Pages 1017-1022

  Calò, Lorenzo A ^a   Facco, Monica ^a   Davis, Paul A ^b   Pagnin, Elisa ^a   Maso, Lucia Dal ^a   Puato, Massimo ^a   Caielli, Paola ^a   Agostini, Carlo ^b   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular remodeling; EPC; heme oxygenase 1; nitric oxide

Indexed keywords

ANGIOTENSIN II; CD133 ANTIGEN; CD34 ANTIGEN; HEME OXYGENASE 1; NITRIC OXIDE; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BARTTER SYNDROME; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL PROGENITOR CELL; FEMALE; GITELMAN SYNDROME; HEALTH STATUS; HUMAN; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; VASODILATATION;

ADULT; ANGIOTENSIN II; ANTIGENS, CD; ANTIGENS, CD34; BARTTER SYNDROME; BRACHIAL ARTERY; ENDOTHELIAL CELLS; FEMALE; GITELMAN SYNDROME; GLYCOPROTEINS; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PEPTIDES; SIGNAL TRANSDUCTION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASODILATION;

EID: 80052495413     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.72     Document Type: Article

References (48)

1. Reidy MA, Schwartz SM. Endothelial regeneration. III. Time course of intimal changes after small defined injury to rat aortic endothelium. Lab Invest 1981; 44: 301-308. (Pubitemid 11156721)
2. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, Nickenig G. Bone marrowderived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22: 1567-1572.
3. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005; 23: 1831-1837. (Pubitemid 41830423)
4. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007. (Pubitemid 41262334)
5. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23: 97-104. (Pubitemid 40128986)
6. Yao E-H, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007; 30: 1119-1128.
7. Honda A, Matsuura K, Fukushima N, Tsurumi Y, Kasanuki H, Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPARg-dependent PI3K/Akt pathway. Atherosclerosis 2009; 205: 376-384.
8. Fadini GP, Avogaro A. Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovasc Res 2010; 87: 12-21.
9. Kim YM, Pae HO, Park JE, Lee YC, Woo JM, Kim NH, Choi YK, Lee BS, Kim SR, Chung HT. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010; 14: 137-167.
10. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046. (Pubitemid 17049750)
11. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, Ingelfinger JR, Ohno M. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 2000; 35: 800-806. (Pubitemid 30165329)
12. Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007; 50: 636-642. (Pubitemid 47442726)
13. Stocker R, Perrella MA. Heme oxygenase-1. A novel drug target for atherosclerotic diseases? Circulation 2006; 114: 2178-2189. (Pubitemid 44747899)
14. Wu BJ, Midwinter RG, Cassano C, Beck K, Wang Y, Changsiri D, Gamble JR, Stocker R. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009; 29: 1537-1542.
15. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96: 65-78.
16. Cal LA. Vascular tone control in humans: the utility of studies in Bartter's/Gitelman's syndromes. Kidney Int 2006; 69: 963-966.
17. Calò LA, Pessina AC, Semplicini A. Angiotensin II signaling in the Bartter' and Gitelman's syndromes, a negative human model of hypertension. High Blood Press Cardiovasc Prev 2005; 12: 17-26. (Pubitemid 41032054)
18. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25: 259-264. (Pubitemid 46071919)
19. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23: 2804-2809.
20. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P, Semplicini A, Palatini P, D'Angelo A, Pessina AC. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009; 32: 832-836.
21. Calò L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60: 882-889. (Pubitemid 34205788)
22. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89: 4153-4157. (Pubitemid 39071528)
23. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, Pessina AC. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26: 938-945. (Pubitemid 351520981)
24. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22: 1963-1969. (Pubitemid 39336679)
25. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes. Relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18: 1200-1205. (Pubitemid 41337973)
26. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006; 29: 469-471. (Pubitemid 44106550)
27. Calò LA, Davis PA, Palatini P, Semplicini A, Pessina AC. Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: study in Bartter's/Gitelman's syndromes and relevance for hypertension. J Hum Hypertens 2007; 21: 904-906. (Pubitemid 350020343)
28. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, Pessina AC. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010; 28: 111-118.
29. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, Zambon S, Cantaro S, D'Angelo A, Davis PA, Manzato E, Crepaldi G. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16: 1001-1008. (Pubitemid 28367955)
30. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518-1525. (Pubitemid 36939623)
31. Calo L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, D'Angelo A. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51: 12-17. (Pubitemid 29027401)
32. Calo L, D'Angelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, Borsatti A. Increased urinary NO2-/NO3-and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874-879.
33. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 2004; 109: 2993-2999.
34. Fadini GP, Schiavon M, Cantini M, Baesso I, Facco M, Miorin M, Tassinato M, de Kreutzenberg SV, Avogaro A, Agostini C. Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 2006; 24: 1806-1813. (Pubitemid 44474194)
35. Asahara T, Murohara T, Sullivan A. Isolation of putative endothelial progenitor cells for angiogenesis. Science 1997; 275: 964-967. (Pubitemid 27087709)
36. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-353. (Pubitemid 39100452)
37. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600. (Pubitemid 36204953)
38. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: e1-e7.
39. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27. (Pubitemid 20209468)
40. Haendeler J, Hoffmann J, Diehl F, Vasa M, Spyridopoulos I, Zeiher AM, Dimmeler S. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004; 94: 768-775. (Pubitemid 38451738)
41. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 392-397. (Pubitemid 46442896)
42. Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 2010; 56: 325-330.
43. Rosso A, Balsamo A, Gambino R, Dentelli P, Falcioni R, Cassader M, Pegoraro L, Pagano G, Brizzi MF. p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem 2006; 281: 4339-4347. (Pubitemid 43847865)
44. Zhou Z, Peng J, Wang C-J, Li D, Li T-T, Hu C-P, Chen XP, Li YJ. Accelerated senescence of endothelial progenitor cells in hypertension is related to the reduction of calcitonin gene-related peptide. J Hypertens 2010; 28: 931-939.
45. Peng J, Lu R, Ye F, Deng H-W, Li Y-J. The heme oxygenase pathway is involved in calcitonin gene-related peptide-mediated delayed cardioprotection induced by monophosphoryl lipid A in rats. Regul Pept 2002; 103: 1-7. (Pubitemid 34001630)
46. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009; 13: 87-102.
47. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-1595.
48. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008; 197: 496-503.